Stay updated with breaking news from Patrick Wingrove. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Patrick Wingrove (Reuters) -Novo Nordisk said on Thursday it sued one compounding pharmacy and refiled a lawsuit against another after finding their ...
Eleven people suffered bouts of dangerously low blood sugar in Lebanon this year, one of whom required hospitalization, after injecting suspected fake versions of Novo Nordisk's diabetes drug Ozempic, according Lebanese health officials. A director for the Lebanese Ministry of Public Health, Rita Karam, said officials suspected the drugs were fake after discovering the doses were different from the ones calibrated for authentic Ozempic injector pens. Explosive demand for Ozempic and other drugs used for weight loss, including Eli Lilly's Mounjaro and Novo's Wegovy, is fueling ...
Eleven people suffered bouts of dangerously low blood sugar in Lebanon this year, one of whom required hospitalization, after injecting suspected fake versions of Novo Nordisk's diabetes drug...
(Reuters) -Eleven people suffered bouts of dangerously low blood sugar in Lebanon this year, one of whom required hospitalization, after injecting suspected fake versions of Novo Nordisk's diabetes drug Ozempic, according Lebanese health officials. A director for the Lebanese Ministry of Public Health, Rita Karam, said officials suspected the drugs were fake after discovering the doses were different from the ones calibrated for authentic Ozempic injector pens. Explosive demand for Ozempic and o
Novo Nordisk on Saturday said the heart protective benefits of its wildly popular Wegovy obesity treatment are due to more than weight loss alone, according to new data presented at a major medical meeting on Saturday. Early data from the Danish drugmaker's Select trial released in August demonstrated that Wegovy, which has been shown to help patients lose an average of 15% of their weight, also reduced incidence of heart attack, stroke or death from heart disease by 20%. Full results from the study, presented at the American Heart Association annual scientific meeting in Philadelphia a...